Segment (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of Segment Reporting Information, by Segment

Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):


	Three Months Ended March 31,
		March 31, 2025		March 31, 2024
Revenue:
Testing revenue		$	107,309	$	90,303
Product revenue		3,580		3,537
Biopharmaceutical and other revenue		3,584		3,004
Total revenue		114,473		96,844
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense		13,067		11,918
Sample collection expense		2,825		3,057
Compensation expense		5,611		5,215
Other cost of testing revenue (1)		3,385		2,846
Allocation of facilities and IT expenses		3,372		2,943
Total cost of testing revenue		28,260		25,979
Cost of product revenue:
Product costs		109		1,263
License fees and royalties		324		436
Other cost of product revenue (2)		792		824
Allocation of facilities and IT expenses		197		121
Total cost of product revenue		1,422		2,644
Cost of biopharmaceutical and other revenue:
Compensation expense		1,240		1,462
Other cost of biopharmaceutical and other revenue (3)		1,044		949
Allocation of facilities and IT expenses		414		427
Total cost of biopharmaceutical and other revenue		2,698		2,838
Intangible asset amortization - cost of revenue		2,585		2,915
Gross profit		79,508		62,468
Operating expenses:
Research and development:
Compensation expense		9,748		9,085
Direct research and development expense		4,141		3,874
Other research and development expenses (4)		1,815		1,519
Allocation of facilities and IT expenses		2,016		1,487
Total research and development		17,720		15,965
Selling and marketing:
Compensation expense		17,635		17,622
Direct marketing expense		710		1,138
Other selling and marketing expenses (5)		3,853		3,414
Allocation of facilities and IT expenses		2,256		1,608
Total selling and marketing		24,454		23,782
General and administrative:
Compensation expense		20,173		17,759
Other general and administrative expenses (6)		21,890		15,037
Allocation of facilities and IT expenses		(8,255)		(6,586)
Total general and administrative		33,808		26,210

Intangible asset amortization - operating expenses		622		738
Other income, net		(4,524)		(2,748)
Income tax provision (benefit)		381		(44)
Net income (loss)		$	7,047	$	(1,864)

________________

(1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses.

(2)Other cost of product revenue includes license fees and royalties, depreciation and amortization and other expenses.

(3)Other cost of biopharmaceutical and other revenue includes license fees and royalties, depreciation and amortization and other expenses.

(4)Other research and development expenses includes depreciation and amortization and other expenses.

(5)Other selling and marketing expenses includes travel, entertainment, conference and other expenses.

(6)Other general and administrative expenses includes professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.